FIELD: pharmaceutically acceptable salts.
SUBSTANCE: invention relates to a compound or a pharmaceutically acceptable salt thereof, having the properties of an HDAC6 inhibitor, and a pharmaceutical composition based on them. In the general formula (I) 
is a single bond or a double bond; n is 0 or 1; each of T1, T2 is independently selected from the group consisting of CH, CH2, -C(=O)- and N; T3 is C or N; each of Z1, Z2, Z3 is independently CH or N; L1 is selected from the group consisting of a single bond, -NH- and -C(=O)-NH-; R1 is selected from the group consisting of C1-3-alkyl, phenyl or 6-membered heteroaryl, each of which is optionally substituted with 1, 2 or 3 R; R2 is -H or F; ring A is selected from the group consisting of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 1,3-dioxolanyl and 1,4-dioxanyl; R is F; "hetero" in a 6-membered heteroaryl is -NH-; in any of the above cases, the number of heteroatoms or heteroatomic group is independently selected from 1 or 2.
EFFECT: providing compounds of formula (I) having HDAC6 inhibitory properties.
22 cl, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CDK4/6 INHIBITOR | 2017 |
|
RU2747311C2 |
| THIOPHENE COMPOUND, ITS PRODUCTION METHOD AND ITS PHARMACEUTICAL APPLICATION | 2017 |
|
RU2709473C1 |
| DERIVATIVE WITH CONDENSED RING AS A RECEPTOR INHIBITOR | 2018 |
|
RU2748993C1 |
| QUINOLINE DERIVATIVES AS SMO INHIBITORS | 2015 |
|
RU2695815C2 |
| PYRIMIDINES AND THEIR OPTIONS, AND THEIR APPLICATION | 2017 |
|
RU2760733C2 |
| RESORCINOL DERIVATIVE AS HSP90 INHIBITOR | 2016 |
|
RU2697703C2 |
| SUBSTITUTED INDOLE COMPOUNDS AS REDUCING REGULATORS OF ESTROGEN RECEPTORS | 2017 |
|
RU2722441C2 |
| PYRAZINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2809631C2 |
| THIENODIAZEPINE DERIVATIVES AND THEIR USE | 2018 |
|
RU2795005C2 |
| DERIVATIVE BASED ON DIHYDROPYRIMIDO-RING AS HBV INHIBITOR | 2015 |
|
RU2693897C2 |
